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There is increasing evidence that chronic enhanced exoge- 
nous or endogenous catecholamine stimulation in patients 
with dilated cardiomyopathy may worsen hemodynamic 
status and prognosis. The cause of this deterioration may lie 
in myocellular calcium accumulation and microcirculatory 
disorders. 
In a prospective study, the calcium channel antagonist 
diltiazem was given to 22 patients with dilated cardiomy- 
opathy (60 to 90 mg three times daily) in addition to 
conventional therapy of digitalis, diuretics and vasodila- 
tors. Twenty-five patients received the conventional ther- 
apy and served as historical controls. Eight additional 
patients who were not originally included in this control 
group received adjunctive diltiazem treatment after ini- 
tially receiving conventional therapy alone. The three pa- 
tient groups were similar in all hemodynamic and anam- 
Dilated cardiomyopathy is the myocardial disease with the 
poorest prognosis (1,2). Its pathogenesis is unknown, but 
there is clinical and experimental evidence that it is related 
to microcirculatory disorders (3,4). Patients have abnormal 
thallium-201 scans (5) and reduced coronary flow rate at rest 
and during pharmacologic vasodilation (6,7). Investigators 
(8,9) have detected in the cardiomyopathic Syrian hamster 
microcirculatory disorders that may be due to vascular 
spasm or obstruction and that can be prevented by pretreat- 
ment with verapamil and hydralazine. Others (10-12) have 
suggested that increased transmembral calcium influx will 
cause hypercontraction with consecutive myocytolysis. 
On the basis of these findings, it seems reasonable to 
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nestic features. Only patients with reduced myofihrillar 
volume fraction on myocardial biopsy were included in the 
trial, because they could be expected to show hemodynamic 
deterioration. 
The mean survival time was 29 months in the control 
group, whereas no patient in the diltiazem group died over 
a mean follow-up period of 15.4 months (p < 0.001). Mean 
left ventricular ejection fraction increased from 0.34 to 0.44 
(p < 0.001) and New York Heart Association functional 
class improved significantly in the diltiazem group and 
during the diltiazem period in the crossover patients, but 
deteriorated in the control group. 
The results suggest that adjunctive diltiazem treatment 
in dilated cardiomyopathy has beneficial effects on mortal- 
ity, hemodynamics and symptoms. 
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study the effect of calcium antagonist treatment in patients 
with dilated cardiomyopathy. Because the calcium antago- 
nist diltiazem can be applied safely even in patients with 
severe congestive heart failure (13-W, the present study 
compared survival, hemodynamics and clinical complaints 
in patients treated with diltiazem in addition to conventional 
therapy with findings in another historical group from the 
same institution treated only conventionally. 
Study protocol. All patients underwent an admission 
standard left heart catheterization (by the Sones or Judkins 
technique), Swan-Ganz catheterization with simultaneously 
gated blood pool scanning at rest and during exercise stress 
testing and left ventricular endomyocardial biopsy, evalu- 
ated by histomorphometric methods including determination 
of the myocytal volume fraction of myofibrils, average 
muscle fiber diameter and volume fraction of interstitial 
structured tissue. (For technical details regarding left and 
right heart catheterization, gated blood pool scanning, exer- 
cise testing and characteristic cardiac biopsy findings con- 
trasted with normal biopsy results, see References 16,17.) A 
clinical evaluation with laboratory tests was included. Dil- 
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tiazem plasma concentrations were measured at the Institute Table 1. Characteristics of 47 Patients at the Beginning of 
for Microanalytics in Hamburg. the Study* 
Reexamination of the patients, including Swan-Ganz 
catheterization and gated blood pool scanning, was done 
every 6 to 24 months. The hemodynamic course, clinical 
symptoms and survival could therefore be determined. 
Means 
Control Group Diltiazem 
(nondiltiazem) Group 
(n = 25) (n = 22) 
Study patients. The 55 patients included in this study (25 
conventionally treated control subjects, 22 treated with 
diltiazem and 8 patients initially treated conventionally with 
later crossover to diltiazem treatment) were treated in our 
clinic between November 1979 and March 1987. A precise 
clinical diagnostic evaluation revealed no illness superim- 
posed on the patients’ heart disease. Invasive diagnostic 
procedures demonstrated dilated cardiomyopathy as defined 
by the World Health Organization/International Society and 
Federation of Cardiology task force (18). All patients were 
subsequently restudied or died before restudy. 
Clinical features* 
Age (years) 
% Men 
Incidence of left bundle 
branch block (%) 
Duration of preclinical 
symptoms (months) 
Myofibril concentration (%) 
Cardiothoracic ratio 
Echo end-diastolic 
diameter (mm) 
Heart rate (beats/min) 
Peak systolic pressure at rest 
(mm Hg) 
Left ventricular end-diastolic 
volume index (mIfm’) 
Left ventricular end-systolic 
volume index (ml/m’) 
Left ventricular ejection fraction 
Incidence of mitral regurgitation (%) 
New York Heart Association 
functional class (no.) 
43.4 46.6 
92 82 
28 27 
9.5 
53 52 
0.52 0.53 
69 67 
To be included in the study, patients had to satisfy the 
following hemodynamic criteria at the time of initial exam- 
ination: 1) rest left ventricular ejection fraction ~0.60, or 2) 
end-diastolic volume index >lOO ml/m* and end systolic 
volume index >40 ml/m*, or both, in combination with mean 
pulmonary artery pressure >35 mm Hg during maximal 
exercise. Patients were considered not to have dilated car- 
diomyopathy and were excluded from study if they had 
coronary heart disease, systemic hypertension, hypertrophic 
cardiomyopathy, car pulmonale, valvular heart disease, 
predominant pericardial disease or systemic diseases of the 
heart muscle. Because the course of the disease varies 
(16,19), all patients included in this study had a reduced 
myofibrillar volume fraction on endomyocardial biopsy, 
which we believe to be the most sensitive and specific 
indicator for further hemodynamic deterioration or death in 
individual patients (16,17). 
91 
114 
144 
91 
Alcohol consumptiont (no.) 
0.33 0.34 
24 45 
I=2 I=1 
II = 8 II = 9 
III = 12 III = 8 
IV = 3 IV = 4 
0=4 0=2 
I = 10 I= 11 
II = 4 II = 5 
III = 1 III = 4 
Patient characteristics of the control group and diltiazem 
group at the time of entry into the study are summarized in 
Table 1. Although some of the control patients had entered 
this trial at a slightly earlier date and are therefore catego- 
rized as a historical control group, no significant difference 
was found between the two groups, especially in hemody- 
namic status, myofibrillar volume fraction, therapy and 
anamnestic features. All patients gave formal consent, and 
the hospital’s ethics committee had approved this study. 
Medication (%) 
Digitalis 
Nitrates 
Vasodilators 
Antiarrhythmic agents 
Class I 
Class III 
Anticoagulation 
Beta-adrenergic blockers 
Diuretics 
84 86 
44 9 
24$ 22$ 
40 36 
8 5 
52 57 
12 0 
44 59 
Therapy. Twenty-five patients were treated according to 
the degree of heart failure with conventional agents including 
digitalis, diuretics and vasodilators. Antiarrhythmic agents 
were given when consecutive ventricular ectopic beats could 
be detected on a 24 hour Holter monitoring electrocardio- 
gram (ECG). These agents were mexiletine, propafenone, 
flecainide (class I) or amiodarone (class III) or beta-receptor 
blockers (class II). 
*Differences between groups were not significant (p > 0.05) for all clinical 
features. tAlcoho1 consumption was graded: 0 = no alcohol; I = alcohol only 
rarely; II = regular alcohol consumption with a daily dose <50 g; III = alcohol 
consumption with a daily dose 250 g; Sfive patients in each group received 
angiotensin-converting enzyme inhibitors. 
Twenty-two similar patients were randomly selected to 
receive diltiazem therapy in addition to conventional ther- 
apy. Diltiazem (Dilzem, Godecke AG) was administered 
within 1 week of study entry in an increasing dosage of 60 mg 
three times daily in patients with a body weight 550 kg, or 90 
mg three times daily in those weighing >.50 kg. Beta-receptor 
blockers and other calcium antagonists were omitted during 
diltiazem therapy (Table 1). 
Because of the apparent beneficial effects of diltiazem, an 
additional group of eight patients who were not originally 
9.9 
93 
114 
140 
93 
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included in the control group because of the lack of prospec- 
tive sequential reexaminations crossed over from conven- 
tional therapy to adjunctive diltiazem therapy. Results in this 
treatment group are summarized separately from results in 
the other patients. 
Classification of patients. All patients were seen at regular 
intervals (6 to 24 months) for follow-up examinations. The 
patients’ functional state was considered to have deterio- 
rated or improved if, in the time between two examinations, 
changes in two of three of the following variables of cardiac 
performance exceeded the level of significance: left ventric- 
ular ejection fraction decrease or increase >0.05, maximal 
pulmonary artery pressure at comparable work loads in- 
crease or decrease >3 mm Hg and peak systolic pressure/ 
end-systolic volume index decrease or increase >0.03 mm 
Hglml’ per m2. The latter variable served as an index of 
manifest left ventricular contractility (20,21). Changes within 
these limits were considered to be insignificant and the 
hemodynamic course was classified as unchanged. 
Statistics. The cumulative mortality of both treatment 
groups was determined with the Kaplan-Meier method, and 
both curves were compared with the likelihood ratio test. 
The patient characteristics listed in Table 1 were compared 
with the Wilcoxon range test (two-tailed). Discrete variables 
within groups were tested with contingency tables in com- 
bination with the chi-square test. The hemodynamic course 
in patients was tested with the paired signed Wilcoxon-range 
test; p values (0.05 were considered to be significant. 
Results 
Cumulative survival curves of control and diltiazem groups 
(Fig. 1). In the historical control group (conventional ther- 
apy alone) the mean survival time was only 29 months, and 
the average yearly mortality rate was approximately 20%; no 
patient in the diltiazem group died (p < 0.001). 
Hemodynamic course of control and diltiazem patients 
(Fig. 2). In the diltiazem group, 15 of the 22 patients 
manifested hemodynamic improvement within a mean of 
15.4 months; the condition of 6 patients was unchanged, and 
that of 1 patient deteriorated. Nine of the 25 control patients 
died within a mean of 14.8 months before reexamination; of 
the remaining 16 patients, 11 exhibited deterioration within a 
mean of 16.1 months; the condition of 2 patients was 
unchanged and that of 3 was improved. The difference 
between groups according to this classification was signifi- 
cant (p < 0.001). Because of the extended observation 
period in the nondiltiazem group, 10 control patients were 
subsequently reexamined within an additional mean time 
interval of 21.7 months. During this period 4 of the 10 
patients died, 2 received a heart transplant, and 3 had a 
poorer and I an improved hemodynamic status compared 
with that at entry. The mean change in left ventricular 
ejection fraction versus time of the survivors is shown in 
EO- 
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Figure 1. Cumulative survival rate curves (Kaplan-Meier) of pa- 
tients with dilated cardiomyopathy and reduced myofibrillar volume 
fraction on endomyocardial biopsy. Patients were treated with 
conventional therapy (nondiltiazem, lower graph) or with diltiazem 
adjunctive to conventional therapy (dashed line). Two patients 
received a heart transplant (T,) because of intractable heart failure 
and are included in the group of patients who died. Nine control 
patients had died at 15 month follow-up. 
Figure 3. The 22 diltiazem treated patients had a substantial 
increase in ejection fraction during diltiazem treatment (from 
0.34 to 0.44, p < 0.001, no deaths). In contrast, 9 control 
patients died and the remaining 16, who had a higher ejection 
fraction than that of the diltiazem group at entrance, exhib- 
ited a decrease in ejection fraction from 0.41 to 0.37 (p < 
0.05) in a similar study interval. 
In correlation with the left ventricular ejection fraction 
increase, in the diltiazem group the peak systolic pressure/ 
end-systolic volume index increased from 1.7 to 2.1 mm Hgi 
ml per m2 (n = 16, p < 0.05) whereas it decreased in the 
control patients from 2.1 to 1.6 mm Hglml per m2 (n = 12, p 
< 0.05). The mean pulmonary artery pressure at comparable 
levels of exercise decreased in the diltiazem group (from a 
mean of 45 to 37 mm Hg; n = 16; p < 0.001); in the control 
patients for the same period the increase (from 32 to 36 mm 
Hg; n = 11) was not significant. 
Course of left ventricular ejection fraction in the crossover 
patients (Fig. 4). Of the eight patients who crossed over 
from conventional therapy to diltiazem treatment, seven had 
exhibited a decrease in left ventricular ejection fraction 
during the nondiltiazem phase (from a mean of 0.40 to 0.29, 
p < 0.05). during the adjunctive diltiazem treatment, the 
ejection fraction increased in six of the eight patients (mean 
increase from 0.29 to 0.36, p < 0.05). However, one of the 
two patients who had a decrease in ejection fraction while 
receiving diltiazem died of worsening heart failure. 
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Clinical course. The subjective functional class of the 
patients in the nondiltiazem group was unchanged, whereas 
it improved significantly in the diltiazem group (p < 0.02). 
Drug plasma levels. Adverse drug reactions, except for 
first degree atrioventricular block, could not be detected. 
Figure 3. Mean left ventricular ejection fraction (LVEF) at rest 
versus time in those who survived until subsequent reexamination. 
Mean ejection fraction increased in patients receiving diltiazem but 
decreased in the control group over a similar observation period. In 
the control group, nine patients with diminished left ventricular 
ejection fraction died before reexamination. Therefore, in this group 
only the course of the surviving 16 patients could be shown. 
t 50 
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Figure 2. Hemodynamic course in the two treatment 
groups. In the control group, the status was improved in 
3 patients, was unchanged in 2, was worse in 11 within 
a mean of 16.1 months and 9 died before reexamination 
within a mean of 14.8 months. In contrast, in the 
diltiazem group, status was improved in 15 patients, 
unchanged in 6 and worse in only 1; no patient died 
within a mean of 15.4 months (,$ = 17.8, p < 0.001). 
Extended observation was possible in 10 control pa- 
tients. Within a mean period of 21.7 months, 6 of the 10 
died or received a heart transplant and the hemody- 
namic status deteriorated in 3 and improved in only 1 
patient. TX = heart transplant. 
The mean diltiazem plasma level in the diltiazem-treated 
patients was 131 * 80 ng/ml (range 0 to 333), 2 to 16 h after 
the last dose. 
Discussion 
Hypotheses deduced from animal experiments initiated 
this first clinical trial evaluating the effects of calcium 
antagonist therapy in dilated cardiomyopathy. Our results 
Figure 4. Mean left ventricular ejection fraction (LVEF) of an 
additional eight patients who were given diltiazem after they dem- 
onstrated hemodynamic deterioration on conventional therapy. 
Ejection fraction decreased significantly during conventional ther- 
apy, but increased in six of the eight patients after adjunctive 
diltiazem treatment. One patient (pt.) died despite diltiazem 
treatment. 
LVEF 
t 
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suggest that the calcium antagonist diltiazem given in addi- 
tion to conventional therapy reduced mortality significantly, 
and improved myocardial function and clinical status of 
patients with dilated cardiomyopathy. However, the treat- 
ment group is compared with a historical control group of 
patients. Although the two groups had similar prognostic 
characteristics at entry, such as hemodynamic status, anam- 
nestic features, duration of preclinical symptoms and drink- 
ing habits in addition to the histologic factor of reduced 
myofibrillar volume fraction, which is a very sensitive and 
specific prognostic factor (16,17), unknown biases in the 
assignment of patients to treatment and control groups 
cannot be ruled out. In a previous study (22) comparing 
randomized versus historical control patients for clinical 
trials, the treated patients usually had the same outcome, the 
differences being due to differences in the outcome of control 
groups. However, in the present study the control patients 
had an annual mortality rate similar to that of other patients 
in longitudinal studies in dilated cardiomyopathy (1,2), but 
the treated patients demonstrated a tremendous reduction in 
mortality. 
We attribute the beneficial clinical hemodynamic course 
in this study group to diltiazem therapy. This hypothesis is 
supported by the beneficial effects of adjunctive diltiazem 
treatment noted in the majority of the eight additional 
patients who crossed over from conventional therapy to 
adjunctive diltiazem treatment. 
Possible modes of action of diltiazem in dilated cardiomy- 
opathy. When analyzing the beneficial mode of action of 
diltiazem in dilated cardiomyopathy, we must first consider 
nonspecific actions of diltiazem, that is, actions independent 
of the pathogenesis of dilated cardiomyopathy. First, diltia- 
zem reduces afterload in heart failure, an effect that can 
improve hemodynamics, survival and clinical status (13,14, 
15,23). Second, calcium antagonists can reduce the inci- 
dence of arrhythmias (24) by inhibiting transsarcolemmal 
calcium inflow (25). Finally, they inhibit the effect of cate- 
cholamines, an action that seems to be beneficial in heart 
failure (23). However, we do not think that these nonspecific 
modes of action of diltiazem were primarily responsible for 
our beneficial results because, in a recent study (26) with 
diltiazem in patients with myocardial dysfunction due to 
infarction, mainly those with impaired left ventricular func- 
tion had a poor outcome. 
Specific actions of diltiazem in dilated cardiomyopathy 
may he as follows: 1) Disturbed microcirculation in dilated 
cardiomyopathy is restored through vasodilation of vasocon- 
stricted vessels. as was shown in the cardiomyopathic Syr- 
ian hamster (8,9). 2) Elevated transmembrane calcium in- 
flux, which might increase energy consumption and induce 
mitochondrial calcium accumulation, is inhibited (10-12). 3) 
Myocardial oxygen consumption is reduced, because oxy- 
gen supply might be impeded in dilated cardiomyopathy (27). 
4) Alcohol toxicity, possibly due to sarcolemmal destruction 
and the resulting elevated calcium influx (28), might be 
diminished. 
Conclusions. Hypotheses deduced from animal experi- 
ments initiated this prospective pilot study. Due to the 
nature of an open study, the groups compared here may be 
biased. However, the mortality rate in our control patients 
resembles that of other patients in longitudinal studies in 
dilated cardiomyopathy (1,2), whereas patients in the diltia- 
zem group had a complete survival and remarkable improve- 
ment in hemodynamic and clinical status. Therefore, the 
results of this first clinical trial, which favor the view that 
calcium antagonists have beneficial effects in human dilated 
cardiomyopathy, can and should influence the design of a 
large scale randomized clinical trial addressing this issue 
(29). 
We are grateful to C. Bunker for the preparation of the manuscript. 
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